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Background: Hypoxia inducible factor-1 α (HIF-1α) has been identified as an important novel target in apoptosis
resistance of pediatric tumors such as Rhabdomyosarcoma (RMS) and Ewing’s sarcoma (ES). Evidence suggests that
PI3K/Akt signaling plays a role in regulation of HIF-1α activation as well as apoptosis resistance in various adult
tumors. However the relevance of PI3K/Akt signaling in HIF-1bα activation and apoptosis resistance in childhood
tumors has not been addressed yet. Thus, this study was to investigate whether PI3K/Akt signaling is involved in
hypoxia induced activation of HIF-1α as well as in resistance to hypoxia-induced apoptosis in childhood tumors
such as RMS and ES.
Methods: Constitutive activation of PI3K/Akt signaling was analyzed by Western blotting. Hypoxic activation of
HIF-1α was determined by Western Blot analysis and electrophoretic mobility shift assay. Apoptosis was determined
by flow cytometric analysis of the propidium iodine stained nuclei of cells treated with PI3K inhibitor LY294002 in
combination with either TNF-related apoptosis-inducing ligand (TRAIL) or doxorubicin.
Results: This study demonstrated that PI3K/Akt signaling was constitutively activated in RMS and ES cell lines, A204
and A673, respectively. Targeting PI3K/Akt signaling by the inhibitor LY294002 (30 μM) significantly decreased the
protein expression as well as DNA binding activity of HIF-1α and restored the apoptosis-inducing ability of cells in
hypoxia Additionally, pretreatment with LY294002 sensitized A204 and A673 cells to TRAIL or doxorubicin induced
apoptosis under hypoxia.
Conclusion: These results suggest that the constitutively active PI3K/Akt signaling contributes to hypoxic activation
of HIF-1α as well as HIF1α-mediated apoptosis resistance in RMS and ES cells under hypoxia.
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Hypoxia inducible factor-1 (HIF-1) is the major tran-
scription factor activated to mediate adoptive responses
under hypoxia [1]. HIF-1 is a heterodimeric protein com-
posed of oxygen regulated α and constitutively active β
subunits. When oxygen is present, HIF-1α is hydrox-
ylated by prolylhydroxylases that allows its interaction
with von Hippel Lindau (VHL) complex, leading to* Correspondence: mkiliceren@adu.edu.tr
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reproduction in any medium, provided the orits ubiquitination and proteosomal degradation. In
contrast, when oxygen is not available rate of asparagine
and proline hydroxylation decreases and HIF-1α cannot
bind to VHL complex and remains stabilized. Stabilized
HIF-1α translocates to the nucleus to interact with the co-
activators HIF-1β and p300/CBP which results in tran-
scriptional activation of the various genes including
growth factors, angiogenic factors, anti-apoptotic factors
and the factors involved in anaerobic metabolism [2,3].
HIF-1α is overexpressed in a variety of human tumors
associated with poor prognosis and resistance to
chemotherapy-induced apoptosis [4]. In our previousal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modulating apoptosis resistance in pediatric tumors such
as Rhabdomyosarcoma (RMS) and Ewing’s sarcoma (ES)
[2]. Constitutive activation of phosphatidylinositol 3-kinase
(PI3K), due to a variety of genetic aberrations, is frequently
observed in human cancers and plays a major role in tumor
formation and progression [5,6]. Akt, a serine/threoneine
kinase, is a central mediator of the PI3K with several down-
stream targets. Aberrant activation of PI3K/Akt plays im-
portant role in the resistance of tumor cells to anticancer
therapy [7,8]. Emerging evidences suggest that PI3K/Akt
signaling mediates regulation and activation of HIF-1α in
various human cancers [9-11]. However, to date there is
no data signifying the relevance of PI3K/Akt signaling in
activation of HIF-1α and in resistance to apoptosis under
hypoxia in childhood tumors.
RMS is the most common soft tissue sarcoma in chil-
dren and accounts for 23% of all sarcomas, and 7% of all
pediatric malignancies [2,12]. ES is the second most
common primary malignant bone tumor [2,13]. Al-
though the majority of RMS and ES patients with
non-metastatic disease can be cured, the prognosis of
patients with metastatic disease remains inferior [14,15].
Therefore, it is of critical importance to understand the
key factors and molecular pathways in pathogenesis and
survival of RMS and ES in order to develop novel effect-
ive anticancer strategy. Published data indicates that the
increased levels of phosphorylated, hence active, Akt in
childhood cancer samples, including neuroblastoma,
glioblastoma, RMS and ES, is negatively correlated with
patient survival [16-20]. Accordingly, this study was
undertaken to investigate whether constitutive PI3K/Akt
signaling is involved in regulation of HIF-1α activation
as well as resistance to hypoxia-induced apoptosis in hu-
man RMS and ES cell lines A204 and A673, respectively.
Results
PI3K/Akt signaling is constitutively activated in A204 RMS
and A673 ES cells
To assess the role of PI3K pathway in HIF-1α induction
the phosphorylation status of Akt, which was used as
surrogate for PI3K activity, was examined by Western
blot analysis. As shown in Figure 1A and B, A204 and
A673 cells had high levels of Akt phosphorylation on
Ser473 in normoxia. Next we used LY294002, the
pharmacologic inhibitor of PI3K to interfere with phos-
phorylation of Akt, and here we show that upon treat-
ment with LY294002 the level of p-Akt was decreased in
a dose dependent manner in both A204 and A673 cells
in normoxia (Figure 1A, B). To address whether PI3K/
Akt signaling was sustained in hypoxia, phosphorylation
of Akt was examined in the presence or absence of
LY294002 in both normoxia and hypoxia. In addition,
due to the growth factors present in serum, which caninduce Akt phosphorylation, we also tested serum-
deprived cells. Accordingly, pretreatment of A204 and
A673 cells by 30 μM LY294002 decreased phosphoryl-
ation of Akt in both conditions whereas protein levels of
total Akt were not altered (Figure 1C, D). As seen in
Figure 1C and D, levels of p-Akt-Ser473 were similar in
A204 and A673 cells either in normoxia or hypoxia and
did not change by serum deprivation but suppressed by
LY294002 addition. Densitometry analysis also con-
firmed these data (Figure 1E and F) suggesting in A204
and A673 cells in normoxia p-Akt levels when normal-
ized to Akt levels, is significantly decreased in the pres-
ence of LY294002 whether or not FCS is withdrawn. In
contrast, no significant differences were detected in p-Akt
levels between hypoxia and normoxia in both cells. In
hypoxia in A673 cells p-Akt levels again did not change
by serum deprivation whereas it seemed to be increased
in A204 cells though it was not significant. Moreover,
addition of LY294002 was able to suppress p-Akt levels
significantly either in the presence or absence of FCS
also in hypoxia in both cells. Whereas pretreatment of
A204 and A673 cells by 30 μM LY294002 did not alter
the protein levels of total Akt. Hence, we conclude that
levels of p-Akt were sustained in both cells under
hypoxia and did not change by serum deprivation either
in normoxia or hypoxia.
Thus, these data demonstrated that activation of PI3K/
Akt signaling is constitutive in both cell lines in normoxia
and hypoxia, as evidenced by high levels of phosphory-
lated p-Akt-Ser473, the downstream effector of PI3K
(Figure 1C, D).
PI3-K/Akt signaling is involved in hypoxic induction of
HIF-1 alpha protein and DNA binding activity in A204 and
A673 cells
In order to examine whether constitutive activation of
PI3K/Akt signaling is involved in hypoxic induction of
HIF-1α protein, either pretreated with 30 μM of
LY294002, or left untreated (control) A204 and A673
cells were incubated under hypoxic conditions and sub-
sequently subjected to Western blot analysis for
stabilization of HIF-1α protein. As shown in Figure 2A,
HIF-1α protein was stabilized 24 h after exposure to
hypoxia and remained its levels up to 48 h post exposure
in both cell lines. Remarkably, pre-treatment with
LY294002 decreased the expression of HIF-1α suggesting
that induction of HIF-1α by hypoxia requires activation of
PI3K pathway. Further, the effect of PI3K inhibitor on
hypoxia-induced DNA-binding activity of HIF-1α was in-
vestigated by EMSA utilizing a 30 HRE-derived oligo-
nucleotide probe. Using a mutant probe, performing
competition assays (Figure 2B) confirmed the identity of
the HIF-1α band. Under hypoxic conditions HIF-1α
showed increased DNA-binding activity at 24 h and the
Figure 1 PI3K/Akt signalling is constitutively activated in A204 and A673 cell lines. Protein levels and phosphorylation status of Akt and β-
actin (loading control), were analyzed by Western blotting in A. 24 hours cell culture of A204 cells under normoxia, treated with 0, 10, 20,
30 μmol/L LY294002. B. 24 hours cell culture of A673 cells under normoxia, treated with 0, 10, 20, 30 μmol/L LY294002. C. 24 h culture of A204
cells under normoxia or hypoxia, medium containing either 0% (−) or 10% FCS (+; top) and/or treated with 30 μmol/L LY294002. D. 24 h culture
of A673 cells under normoxia or hypoxia, medium containing either 0% (−) or 10% FCS (+; top) and/or treated with 30 μmol/L LY294002. E.
Western blots obtained as indicated in C were densitometrically analyzed. Shown are means ± SEM of four independent experiments. Statistically
significant differences between LY294002 treated and untreated (20% FCS) are indicated *, p < 0.05 and **, p < 0.01. Statistically significant
differences between LY294002 treated and untreated (0% FCS) are indicated #, p < 0.05 and ##, p < 0.01. The difference between untreated
hypoxic and normoxic condition was not significant (for 20% FCS, p = 0.1288; for 0% FCS, p = 0.8749). F. Western blots obtained as indicated in D
were densitometrically analyzed. Shown are means ± SEM of four independent experiments. Statistically significant differences between LY294002
treated and untreated (20% FCS) are indicated *, p < 0.05 and **, p < 0.01. Statistically significant differences between LY294002 treated and
untreated (0% FCS) are indicated #, p < 0.05 and ##, p < 0.01. The difference between untreated hypoxic and normoxic condition was not
significant (for 20% FCS, p = 0.1529; for 0% FCS, p = 0.3275).
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A673 cells (Figure 2B). Pretreatment with LY294002 re-
duced hypoxia-induced DNA binding activity of HIF-1α in
both cell lines, although this effect was more pronounced
in A204 cells after 24 h compared to A673 cells.
Inhibition of HIF-1α by LY294002 restores apoptosis
inducing ability of A204 and A673 cells under hypoxia
Next, we investigated whether or not decreased stabiliza-
tion and DNA binding activity of HIF-1α by LY294002,
can sensitize A204 and A673 cells to apoptosis un-
der hypoxia. In order to examine long lasting effects
of LY294002, cells were cultured for up to 72 h
under hypoxic conditions in the presence of 30 μMLY294002 and apoptosis was assessed every 24 hours.
As seen in Figure 3A while hypoxia alone did not
trigger apoptosis in both cell lines, pretreatment with
LY294002 induced 15,5 (±1,7)% and 16,0 (±1,1)%
apoptosis in A204 and A673 cells, respectively, in a
time dependent manner (Figure 3A). These data sug-
gest that decreased protein level and DNA binding
activity of HIF-1α by LY294002 treatment restores
apoptosis sensitivity in A204 RMS and A673 ES cells.
In our previous work, we showed that hypoxia pro-
tects against death receptor- (e.g. TRAIL) and cytotoxic
drug- (e.g. Doxorubicin) induced apoptosis in A204 and
A673 cells. Therefore cells were pretreated with
LY294002 and cultured for up to 72 h in the presence or
Figure 2 PI3K/Akt pathway is involved in activation of HIF-1α in A204 and A673 cell lines. Cells were pretreated with 0 or 30 μmol/L of
LY294002 for 1 hour and then incubated for 24 hours or 48 hours either in normoxia (N) or hypoxia (H). A. Protein expression levels of HIF-1α
and β-actin were analyzed by western blotting. B. DNA binding activity of Hif-1α in nuclear extracts was assessed by EMSA. Specific HIF-1 DNA
binding was confirmed by using a radioactive labeled mutated (m) probe, in which the HIF-1α consensus binding site is inactivated, and by
competition with unlabelled consensus (c) and mutant (c/m) DNA probes in 100 fold excess.
Figure 3 Sensitization of A204 and A673 cells to doxorubicin- and TRAIL-induced apoptosis by PI3K inhibition. A204 (A) and A673 (B)
cells were pretreated or not with 30 μmol/L LY294002 for 1 hour, incubated with doxorubicin (0.1 μg/ml) or TRAIL (100 ng/ml) and cultured
under normoxic or hypoxic conditions for up to 72 hours. 24 hours-white bars, 48 hours- black bars, 72 hours-hatched bars. Apoptosis was
determined by FACS analysis of DNA fragmentation of propidium iodide–stained nuclei; the percentage of specific apoptosis is shown. Columns,
mean of three independent experiments done in duplicate; bars, SD. For statistical analysis two-way ANOVA was performed comparing specific
apoptosis of either TRAIL or doxorubicin-induced apoptosis under normoxia vs hypoxia (*p < 0.05, **p < 0.01, ***p < 0.001) and hypoxia induced
apoptosis vs hypoxia + LY294002 (##p < 0.01, ###p < 0.001) as well as hypoxia + TRAIL or doxorubicin vs hypoxia + LY294002 + TRAIL or doxorubicin
(§§p < 0.01, §§§p < 0.001).
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tosis was assessed every 24 hours, and as seen in
Figure 3A, without LY294002 pretreatment, after 72 h
TRAIL - induced apoptosis in normoxia was at least
10% higher than to that of in hypoxia, underlining the
protective role of hypoxia in both cell lines. Interestingly,
pretreatment with LY294002 significantly sensitized cells
for TRAIL-induced apoptosis and rendered the protect-
ive effect of hypoxia (Figure 3A).
Next, the effect of HIF-1α inhibition by LY294002
treatment in combination with doxorubicin, typically
triggering apoptosis via the mitochondrial pathway, was
also tested. In contrast to TRAIL, doxorubicin-induced
apoptosis was substantial in A204 and A673 cells under
either normoxia or hypoxia, though a slight protective
effect of hypoxia was still present. Pretreatment of cells
with LY294002 greatly enhanced doxorubicin-induced
apoptosis. When pretreated with LY294002 the rate of
apoptosis was at least 20% higher in both A204 and
A673 cells after 72 h exposure to hypoxia (Figure 3B).
Moreover, the broad range caspase inhibitor z-VAD-fmk
was used to test requirement for caspases during TRAIL-
or doxorubicin-induced apoptosis under hypoxia. Apop-
tosis induced by combined treatments of LY294002 and
TRAIL, or doxorubicin was significantly blocked in the
presence of z-VAD-fmk under both normoxia and hypoxia
in both cell lines in a time dependent manner (Figure 4A
and B). These results indicated that apoptosis induced by
combined treatments with LY294002 and either TRAIL,
or doxorubicin was mediated by caspases.Discussion
Previously, HIF-1α has been identified as key factor in
conferring resistance to apoptosis under hypoxia in child-
hood tumors such as RMS and ES [2]. Evidences suggest
that PI3K/Akt signaling plays a role in regulation of HIF-1α
activation in various adult tumors [8,21-25]. The present
study was undertaken to investigate the relevance for
PI3K/Akt signaling and HIF-1α activation along with
apoptosis resistance in RMS and ES. Here, it is presented
for the first time that constitutively activated PI3K/Akt
involved in hypoxic activation of HIF-1α and targeting
PI3K/Akt via LY294002 prevented HIF-1α’s stabilization
and restored apoptosis sensitivity of RMS and ES cells
under hypoxic conditions.
The current study provides a number of evidences
supporting this conclusion. First, we demonstrated that
A204 (RMS) and A673 (ES) cell lines show high level of
phosphorylated Akt (on Ser473), sustaining under serum
deprivation and hypoxia indicating to the constitutive
activation of Akt. Our data is consistent with the in vivo
studies, showing the increased abundance of active,
phosphorylated, Akt in several childhood cancers,including RMS and ES [16-20,26]. Second, Akt phosphor-
ylation was inhibited via PI3K inhibitor LY294002 that
also decreased the protein expression and DNA binding
activity of HIF-1α. More importantly inhibition of PI3K/
Akt signaling or HIF-1α activity by LY294002 blocked
protection against hypoxia-induced cell apoptosis. Third,
inhibition of HIF-1α activation via LY294002 also sensi-
tized RMS and ES cells for death receptor (TRAIL) - as
well as drug (Doxorubicin) - induced apoptosis which
could be blocked in the presence of z.VAD. fmk.
Oxygen regulated transcription factor HIF-1α and the
serine/threonine kinase Akt are both essential for devel-
opment and implicated in tumor growth [8,27-31]. They
share the ability to induce processes such as angiogen-
esis, glucose uptake, and glycolysis [29,32-34]. To date
several studies have identified the PI3K/AKT pathway as
an important element in hypoxic induction of HIF-1α
protein and activity in tumor cell lines [9,11,35,36] Also,
in non malignant systems such as developing rat brain
or pulmonary artery smooth muscle cells PI3K/Akt
pathway is involved in activation of HIF-1α [21,37,38].
From our data, we propose that constitutive activation of
the PI3K/Akt contributes to the increased hypoxic activa-
tion of HIF-1α in RMS and ES cells, because inhibiting
PI3K/Akt activity by the inhibitor LY294002 decreased
HIF-1α protein levels and prevented DNA binding activity
under hypoxia. However, there are other reports indicating
the contrary data and suggesting that PI3K/Akt signaling is
neither required nor sufficient for the hypoxic stabilization
or activation of HIF-1α [39,40]. Hence, one possibility is
that the involvement of constitutive PI3K/Akt signaling in
hypoxic activation of HIF-1α may depend on cell type or
on tumor type/stage and its microenvironment.
The PI3K/Akt pathway is also well known to mediate
prosurvival signals. In particular, Akt is involved in inhib-
ition of apoptosis by phosphorylating pro-apoptotic mole-
cules i.e. Bad, Caspase-9 or modulating transcription
factors i.e. c-Raf. [41]. Recent studies have shown that in-
hibition of PI3K/Akt might be a promising strategy to de-
crease the threshold for apoptosis induction via the death
receptor triggering or cytotoxic drugs in neuroblastoma
and glioblastoma [8,26,42]. In line with that our data also
provides evidence that PI3K/Akt inhibition cooperates
with TRAIL or doxorubicin to trigger apoptosis under
hypoxia in RMS or ES cells. Resistance to apoptosis is still
major obstacle in treatment and our findings may have
important implication for apoptosis-based therapy of RMS
and ES. Moreover it provides basis for further investiga-
tion of new generation PI3K inhibitors in combination
with TRAIL or chemotherapy to overcome apoptosis re-
sistance associated with tumor hypoxia. Similarly a previ-
ous report also suggests 3-phosphoinositide-dependant
kinase-1(PDK-1)/Akt pathway as an attractive therapeutic
target in RMS [17].
Figure 4 Sensitization of A204 and A673 cells for doxorubicin- and TRAIL- induced apoptosis is caspase dependent. A204 (A) and A673
(B) cells were pretreated with 0 or 30 μmol/L of LY294002 for 1 hour, and cultured under normoxic or hypoxic conditions with doxorubicin
(0.5 μg/ml) or TRAIL (100 ng/ml) for up to 72 hours with or without or z-VAD-fmk (50 μmol/L) 24 hours-white bars, 48 hours-black bars, 72
hours-hatched bars Columns, mean of three independent experiments done in duplicate; bars, SD. For statistical analysis two-way ANOVA was
performed comparing specific apoptosis of either LY294002 + TRAIL or doxorubicin--induced apoptosis without z-VAD-fmk vs with z-VAD-fmk
under normoxia (*p < 0.05, **p < 0.01) or the same comparison of specific apoptosis under hypoxia (#p < 0.05, ##p < 0.01).
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elucidate the exact role of PI3K/Akt in hypoxic activa-
tion of HIF-1α and to identify the molecules mediating
the sensitization effect of PI3K/Akt.
Conclusion
Constitutive activation of PI3K/Akt involved in hypoxic
activation of HIF-1α in RMS and ES cells. Targeting
PI3K/Akt via LY294002 prevented HIF-1α’s stabilization
and restored apoptosis sensitivity of RMS and ES cells
under hypoxic conditions. The current study identifies
an important link between PI3K/AKT and HIF-1α,
which may have particular relevance to disease progres-
sion as well as therapeutic target for cancer intervention
in RMS and ES.
Materıals and methods
Cell Culture and Hypoxia incubation
Human Rhabdomyosarcoma (A204) and Ewing’s sarcoma
(A673) cell lines were obtained from American Type Cul-
ture Collection (Manassas, VA) and were grown in
Dulbecco’s modified Eagle’s medium (Life Technologies,
Inc., Eggenstein, Germany) containing 10% heat inactivated
fetal calf serum (Biochrom, Berlin, Germany), 100 IU/ml
penicillin, 100 μg/ml streptomycin (Biochrom), 10 mM
glutamine (Biochrom) in a humidified atmosphere at 37 °Cwith 5% CO2 unless otherwise specified. Hypoxic condi-
tions (0.5% O2) were achieved by incubation in a humidi-
fied internal incubator of a hypoxia glove box (Coy
Laboratory Products, Inc.). After an initial exposure to low
oxygen, all subsequent treatments were given within the
glove box to prevent cellular damage due to reoxygenation.
Determination of apoptosis
Apoptosis was assessed by fluorescence-activated cell-
sorting (FACScan, Becton Dickinson, Heidelberg, Germany)
analysis of DNA fragmentation of propidium-iodide stained
nuclei as described previously [2]. The percentage of
specific apoptosis was calculated as follows: 100 × [experi-
mental apoptosis (%) − spontaneous apoptosis (%)] [100%−
spontaneous apoptosis (%)].
Protein extraction and Western blot analysis
Total cell extracts were prepared from cells grown in 6-well
plates at 90% confluence. Cells were exposed to 20% O2
or 0.5% O2 for the indicated time points and lysed in lysis
buffer (20 mM Tris, pH 7.5 (Sigma), 150 mM KCl (Sigma),
1 mM EDTA, 1% Triton X-100 (Sigma) supplemented with
protease inhibitor mixture (CompleteW; Roche Applied Sci-
ence, Mannheim, Germany). 0.2 mM phenylmethylsulfonyl
fluoride (PMSF); 0.5 mM dithiothreitol (DTT) and 1 mM
sodium-ortho-vanadate before use. Western blot analysis
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mouse anti-Hif-1α monoclonal (1:250; BD Biosciences;
Heidelberg, Germany), rabbit anti-phospho Akt (Ser 473)
(D9E) and rabbit anti-Akt (Cell Signaling, Beverly, MA),
followed by goat-anti-mouse IgG or goat-anti-rabbit IgG
conjugated to horseradish peroxidase (1:5,000; Santa Cruz
Biotechnology) [2]. Mouse anti-β-actin monoclonal anti-
body (1: 5000; Sigma), was used as a loading control. All
proteins were visualized using enhanced chemilumines-
cence (Amersham Biosciences).
Nuclear protein extraction and Electrophoretic mobility
shift assay (EMSA)
Nuclear extracts were prepared essentially as described
[2]. Oligonucleotide DNA probes containing the HIF-1α
binding sequence 50-TCTGTACGTGACCACACTCAC
CTC [43] and a mutant probe 50-TCTGTAAAAGA
CCACACTCACCTC, labelled with with γ-32P-ATP
(Amersham, Freiburg, Germany) and annealed with com-
plementary oligonucleotides, were used for EMSA [43].
EMSA was done as described previously [2]. In general,
unless otherwise stated, all qualitative analyses were re-
peated at least three times.
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